Palisade Bio Announces Inducement Grants Underneath Nasdaq Listing Rule 5635(c)(4)


Carlsbad, CA, Sept. 23, 2022 (Globe NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a scientific stage biopharmaceutical corporation advancing therapies for acute and continual gastrointestinal (GI) difficulties, these days announced that it experienced built equity grants to two new workforce beneath its 2021 Inducement Plan.

On August 29, 2022, the Company’s Compensation Committee granted choices to two new non-executive workforce masking an aggregate of 93,000 shares of the Company’s typical stock as content inducements to work in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an physical exercise value equal to the closing selling price of the Company’s popular inventory on the day of grant. The solutions granted to each personnel vest in equal proportions each and every quarter for 3 several years. In all scenarios, the choices are contingent on every single employee’s ongoing company with the Organization at the applicable vesting day.

About Palisade Bio 

Palisade Bio is a late-phase biopharmaceutical company centered on establishing therapeutics that guard the integrity of the intestinal barrier. The Business utilizes in excess of 3 many years of exploration and established science that inbound links the part of intestinal barrier biology and human illness to produce novel therapeutics that concentrate on and strengthen the integrity of the intestinal barrier.

The Company’s direct application, LB1148, is a wide-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, probably lessening intestinal injury. In a number of scientific studies, LB1148 has shown constructive benefits in accelerating the time to return of postoperative bowel perform, and the Organization recently introduced examination that LB1148 lessened the incidence and severity of write-up-surgical belly adhesions. LB1148 is at this time being evaluated in a Section 3 clinical research for accelerating the return of postoperative bowel operate and in a Phase 2 study for the avoidance of write-up-surgical stomach adhesions.

The Firm believes that addressing the disruption of the intestinal barrier has the opportunity to basically adjust the way diseases are handled and to set up new criteria of individual care. For much more info, make sure you go to www.palisadebio.com.

Forward Looking Statements
This communication includes “forward-looking” statements for needs of the risk-free harbor provisions of the Non-public Securities Litigation Reform Act of 1995. Ahead-seeking statements involve statements regarding Palisade’s intentions, beliefs, projections, outlook, analyses or existing expectations regarding, between other things: the likely to fundamentally change the way illnesses are treated, the completion of enrollment for the Stage 3 study, the possible for the statistically sizeable Phase 3 data to let for NDA acceptance, and the probable for LB1148 to establish the typical of treatment, if authorized. Any statements contained in this conversation that are not statements of historical actuality may perhaps be deemed to be forward-hunting statements. These ahead-wanting statements are based upon Palisade’s latest expectations. Forward-hunting statements contain hazards and uncertainties. Palisade’s real results and the timing of functions could vary materially from those anticipated in such forward-seeking statements as a result of these pitfalls and uncertainties, which include things like, devoid of limitation, the company’s capability to progress its scientific systems, the uncertain and time-consuming regulatory approval method the company’s means to attain additional funding to fund scientific progress and the company’s ability to comply with the ongoing listing requirements for Nasdaq. Extra hazards and uncertainties can be observed in Palisade Bio’s Quarterly Report on Form 10-Q for the quarter finished June 30, 2022. Palisade expressly disclaims any obligation or endeavor to release publicly any updates or revisions to any ahead-seeking statements contained herein to reflect any adjust in Palisade’s expectations with regard thereto or any transform in activities, conditions or instances on which any these kinds of statements are dependent.

Investor Relations Get hold of
JTC Staff, LLC
Jenene Thomas
833-475-8247
[email protected]

Resource: Palisade Bio

The information is by GlobeNewswire. DKODING Media is not dependable for the content material presented or any back links similar to this material. DKODING Media is not liable for the correctness, topicality or the excellent of the written content.


Supply : https://www.dkoding.in/press-launch/palisade-bio-announces-inducement-grants-below-nasdaq-listing-rule-5635c4/

Leave a comment